ArticleBMC cancer2026

Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study.

Shuri Aoki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.